Close Menu

Matthew McGrew, Daniel Comas

Feb 02, 2018

Danaher announced Matthew McGrew will become the firm's CFO, effective Jan. 1, 2019. He will replace Daniel Comas, who will continue as an executive vice president and a member of the Office of the Chief Executive as he begins a gradual transition to retirement. McGrew joined Danaher in 2004 as director M&A Finance. He currently is Group CFO of Danaher's Diagnostics and Dental platforms. Comas has been with Danaher since 1991 and became its CFO in 2005. 

More Like This

Feb 23, 2021

Ortho Clinical Diagnostics: Evelyn Dilsaver

Ortho Clinical Diagnostics has appointed Evelyn Dilsaver as a member of its board of directors and chair of its audit committee. From 2004 to 2007, Dilsaver served as the president and CEO of Charles Schwab Investment Management, the mutual fund arm of Charles Schwab, and helped grow the business from $132 billion to more than $200 billion in assets. She also served in leadership roles at Schwab for more than 16 years, including controller and chief of staff to the co-CEO. Dilsaver began her career at Ernst & Young, where she specialized in the banking and savings and loan industries.

Feb 23, 2021

Co-Diagnostics: Brian Brown, Jesse Montgomery, Reed Benson, Brent Satterfield

Co-Diagnostics has appointed Brian Brown as its CFO and Jesse Montgomery as its chief scientific officer (CSO). Co-Diagnostics' former CFO Reed Benson will remain with the company as its general counsel. Further, Brent Satterfield, the firm's founder and former CSO, will continue to be involved as the head of its scientific advisory board. Brown previously held the roles of CFO, vice president of accounting and investor relations, and director of finance for public and private companies.

Feb 23, 2021

Quotient Limited: Manuel Mendez

Quotient Limited has appointed Manuel Mendez its CEO, replacing Franz Walt, who is retiring after serving as CEO since 2018. Mendez has more than 30 years of experience in the diagnostics and life science spaces and was previously at Quest Diagnostics where he was SVP and chief commercial officer. Before that, he was SVP and head of global commercial operations at Qiagen where he was also a member of its executive committee. He has also held senior leadership positions at Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and BioMérieux.

Feb 23, 2021

Qiagen: Thomas Ebeling

Thoms Ebeling has been appointed to Qiagen's supervisory board. Ebeling has been an advisor in recent years to various companies after having served as CEO of German media group ProSiebenSat.1 from 2009 to 2018. Prior to that he worked for Novartis from 1997 to 2008, including as CEO of Novartis Pharmaceuticals and CEO of Novartis Consumer Health. Ebeling has also previously served on the supervisory boards of Bayer and Lonza.

Feb 22, 2021

Aspira Women's Health: Nicole Sandford

Aspira Women's Health has appointed Nicole Sandford to its board of directors. She was previously the executive vice president and global board services leader at Ellig Group, and prior to that Sandford was at Deloitte from 1993 to 2020, most recently as the national managing partner for its regulatory and operational risk practice.

Feb 19, 2021

Siemens Healthineers, Centogene: Peer Schatz

Peer Schatz was elected to the supervisory board of Siemens Healthineers on Feb. 12 at the company's annual shareholders' meeting. The company proposed his addition to the board on Jan. 5.

In addition, Schatz has become chairman of the supervisory board of Centogene, effective Jan. 1, 2021, after having joined the board last summer. He replaced Flemming Ornskov, who was chairman from April 1, 2019 until Dec. 31, 2020.

Schatz is the former CEO of Qiagen, a position he held from 1993 until 2019. He is currently managing director of PS Capital Management and is chairman of the board and cofounder of spatial genomics startup Resolve Biosciences. Before Qiagen, he had various roles at ComputerLand and at Sandoz and cofounded several startup companies in the IT industry. Schatz holds an master's degree in finance from the University of St. Gallen and an MBA from the University of Chicago Graduate School of Business.

Feb 19, 2021

Myriad Genetics: Kevin Haas, Faith Zaslavsky

Myriad Genetics has promoted Kevin Haas and Faith Zaslavsky. Haas, will be Myriad's new chief technology officer and report to CEO Paul Diaz. He has held various senior level positions in R&D, bioinformatics, engineering, and technology since joining the company in 2013. Zaslavsky will be president of the Myriad Oncology business unit, which she has been general manager of since 2019.

Feb 18, 2021

Infinity BiologiX: Shareef Nahas, Sameer Kalghatgi

Infinify BiologiX (IBX) has named Shareef Nahas as vice president of global laboratory operations and clinical services and interim CSO, and Sameer Kalghatgi as senior director of laboratory operations.

Nahas will report to Robin Grimwood, president and interim CEO of IBX. Nahas and Grimwood assume their interim roles following the recent passing of Andrew Brooks. Nahas was previously senior director of operations at Rady Children's Institute of Genomic Medicine in San Diego. Prior to that he held a number of senior laboratory roles at Genoptix (Novartis) and Ambry Genetics. He received his PhD in molecular toxicology from the University of California, Los Angeles.

Kalghatgi joins IBX from Coriell Institute for Medical Research, where he served as director of laboratory operations. He will report to Nahas at IBX.

IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. Its COVID-19 saliva test was the first to receive US Food and Drug Administration Emergency Use Authorization. The company primarily provides sample collection, processing, storage, and analytical services to research and clinical customers.

Feb 18, 2021

Delfi Diagnostics: Tara Maddala, Allison Ryan

Delfi Diagnostics has appointed Tara Maddala as its VP of clinical development and Allison Ryan as VP of data science. Maddala previously served as VP of biostatistics and data managment at Grail. Ryan previously served as VP of data science at Natera. 

Feb 16, 2021

NephroSant: Mark Capone

Mark Capone has joined the board of directors of NephroSant, a spinout from the University of California, San Francisco that is developing noninvasive testing solutions for kidney health. He is the president and CEO of Precision Medicine Advisors. Before that, he was president and CEO of Myriad Genetics, and prior to that, he held various positions at Eli Lilly. Capone holds a BS in chemical engineering from Penn State University and an MS in chemical engineering and in management from the Massachusetts Institute of Technology.

Feb 16, 2021

1health: Mostafa Ronaghi

Testing-as-a-service company 1health has appointed Mostafa Ronaghi to its board of directors. Ronaghi was chief technology and senior vice president at Illumina for about 13 years. He also cofounded the Illumina Accelerator and spinoff company Grail. Ronaghi also cofounded several other genomics and life science data ventures, including Avantome, ParAllele Bioscience, NextBio, and Pyrosequencing. Prior to these ventures, he was a principal investigator at Stanford University from 1999 to 2008, focusing on the development of molecular diagnostic applications.

Feb 12, 2021

LexaGene: Daryl Rebeck, Stephen Mastrocola

LexaGene said this week that Daryl Rebeck will resign from the company's board and his position as president effective Feb. 15. The company also said that Stephen Mastrocola has joined the board of directors. Mastrocola recently retired from Ernst & Young after 19 years, where he was a senior assurance partner and led the firm's New England Assurance Practice for several years. Prior to this, he was an assurance partner at Arthur Andersen.

Feb 10, 2021

Sema4: Nat Turner, Emily Leproust, Eli Casdin

Sema4 has appointed three new members to its board of directors, who will take up their posts after the firm has gone public through a planned merger with special purpose acquisition company CM Life Sciences.

The new members are Nat Turner, cofounder and CEO of Flatiron Health; Emily Leproust, cofounder and CEO of Twist Bioscience; and Eli Casdin, founder and chief investment officer of Casdin Capital.

Feb 09, 2021

LabCorp: Prasanth Reddy, Robert Phillips

Laboratory Corporation of America has appointed Prasanth Reddy its SVP and enterprise oncology head of the firm's enterprise oncology unit, and Robert Phillips its VP and head of enterprise oncology science. The enterprise oncology unit will leverage LabCorp's drug development and diagnostics businesses to personalize cancer treatments for patients, the Burlington, North Carolina-based company said. Reddy was most recently VP of medical affairs at Foundation Medicine. Before that, he developed oncology service line treatment pathways at the Adventist Health System. Phillips joins LabCorp from Daiichi-Sankyo where he was VP and head of translational science and oversaw that firm's companion diagnostics efforts. He also was VP and head of precision medicine at Pfizer and was head of precision medicine at Regeneron Pharmaceuticals where he also founded the Regeneron Genetics Center.

Feb 08, 2021

DermTech: Lisa Beck, George Han

DermTech has appointed Lisa Beck and George Han to its scientific advisory board.

Beck is co-director of the University of Rochester Medical Center for Allergic Disease and has served on the board of the directors of the International Eczema Council since 2014. She also serves as president-elect of the Society of Investigative Dermatology. 

Han currently serves as the systems medical director for dermatology and chief of teledermatology at Mount Sinai Health System. He is also the current VP of the Dermatologic Society of Greater New York and a member of the Medical Board of the National Psoriasis Foundation.